CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors.

Continued here:
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *